Profile: Caladrius Biosciences Inc (CLBS.OQ)
17 May 2019
Caladrius Biosciences, Inc. incorporated on October 18, 1980, is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation.
The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis. The Company's T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases beyond its target indication of TID. Its other technologies include tumor cell/dendritic cell technology for immuno-oncology and CD34 technology for ischemic repair. The Company operates over two facilities, approximately one in Allendale, New Jersey, and over one in Mountain View, California.
The Company competes with Lonza Group Ltd. and WuXi AppTec.
Caladrius Biosciences Inc
110 Allen Rd
BASKING RIDGE NJ 07920-4500